Sexyy Red Has Fans Fawning Over Her Natural Hair In New Social Media Post
Direxion Daily MSFT Bull 2X Shares ( NASDAQ:MSFU – Get Free Report ) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 190,200 shares, an increase of 60.0% from the November 30th total of 118,900 shares. Based on an average daily trading volume, of 471,600 shares, the days-to-cover ratio is presently 0.4 days. Hedge Funds Weigh In On Direxion Daily MSFT Bull 2X Shares Hedge funds and other institutional investors have recently bought and sold shares of the company. Flow Traders U.S. LLC acquired a new stake in Direxion Daily MSFT Bull 2X Shares during the 3rd quarter worth approximately $1,191,000. Client First Investment Management LLC purchased a new stake in shares of Direxion Daily MSFT Bull 2X Shares during the second quarter worth $291,000. Finally, Hollencrest Capital Management acquired a new stake in shares of Direxion Daily MSFT Bull 2X Shares in the second quarter valued at $50,000. Direxion Daily MSFT Bull 2X Shares Price Performance Shares of MSFU opened at $41.27 on Friday. The firm has a 50-day simple moving average of $42.71 and a two-hundred day simple moving average of $44.22. Direxion Daily MSFT Bull 2X Shares has a 1-year low of $36.29 and a 1-year high of $54.39. The stock has a market cap of $127.11 million, a PE ratio of 43.52 and a beta of -2.33. Direxion Daily MSFT Bull 2X Shares Cuts Dividend About Direxion Daily MSFT Bull 2X Shares ( Get Free Report ) The Direxion Daily MSFT Bull 1.5X Shares ETF (MSFU) is an exchange-traded fund that is based on the Microsoft Corporation index. The fund provides 1.5x leveraged exposure, less fees and expenses, to the daily price movement for shares of Microsoft stock. MSFU was launched on Sep 7, 2022 and is managed by Direxion. Read More Receive News & Ratings for Direxion Daily MSFT Bull 2X Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Direxion Daily MSFT Bull 2X Shares and related companies with MarketBeat.com's FREE daily email newsletter .
Die Welt opinion editor resigns over Elon Musk article in support of AfD
Massimo Group (NASDAQ:MAMO) Short Interest Update
The remaining members of are to reunite onstage for a show next week at the 1100-capacity Showbox in Seattle, WA. Billed as Nudedragons, the name Soundgarden initially reunited under in 2010 (and an anagram of Soundgarden), the December 14 show will be Kim Thayil, Ben Shepherd and Matt Cameron's first together since joining Brandi Carlisle for performances of and during her show at the Gorge Amphitheatre in Gorge, WA, in 2021. "Nudedragons will be returning to the stage, and the Showbox, for the first time in 14+ years as part of the SMooCH benefit for Seattle Children’s Hospital on Saturday, December 14," say the band on social media. "Shaina Shepherd will be featured on vocals for their brief encore performance. Shepherd is a Seattle-based singer, songwriter, music educator and community organizer who released a cover of Sam Cooke's classic in 2000 accompanied by bassist Duff McKagan and drummer Chad Smith. SMooCH was started by musicians Pete and Brandy Nordstrom in 2012 after their infant son received life-saving treatment from Seattle Children’s Hospital. Previous benefit shows have starred the likes of Modest Mouse, Iron And Wine, Jason Isbell, J. Mascis, the Afghan Whigs and Redd Kross. Last year’s event generated more than $2.6 million. Tickets and VIP packages for the show, which also features McKagan, Sebadoh and Doug Martsch of Built Spill (VIP only), are already sold out. . Sign up below to get the latest from Classic Rock, plus exclusive special offers, direct to your inbox! “Over the last 10 years, I’ve been a bit disillusioned by popular music. The business sucks.” A revitalised Trent Reznor is ready to to be “back in the driver’s seat” again with a new Nine Inch Nails project “This one shifts gears from the fast and furious energy of our two recent singles”: Hear Arch Enemy put the “melodic” into “melodic death metal” on new single Blood Dynasty Live Is But A Dream...: Avenged Sevenfold announce European summer tour for 2025 Online Editor at Louder/Classic Rock magazine since 2014. 38 years in music industry, online for 25. Also bylines for: Metal Hammer, Prog Magazine, The Word Magazine, The Guardian, The New Statesman, Saga, Music365. Former Head of Music at Xfm Radio, A&R at Fiction Records, early blogger, ex-roadie, published author. Once appeared in a Cure video dressed as a cowboy, and thinks any situation can be improved by the introduction of cats. Favourite Serbian trumpeter: Dejan Petrović.Linq Launches Blue Messages for Sales
Unlike scores of people who for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It’s a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It’s all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person’s response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn’t happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It’s not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn’t respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I’m hoping it’s slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press
HENDERSON, Nev. (AP) — Ashlon Jackson scored a career-high 30 points and No. 14 Duke defeated No. 10 Kansas State, 73-62 on Monday, in the semifinals of the Ball Dawgs Classic. The Blue Devils (6-1) overcame an early 11-point deficit behind Jackon’s shooting hand to advance to Wednesday’s championship game against the winner of the game between No. 9 Oklahoma and DePaul. Jackson, who has scored in double figures in all six of Duke’s games, shot 12 of 19 (63.1%) from the floor, including 6 of 9 (66.7%) from 3-point range. Reigan Richardson added 16 points for the Blue Devils. Kansas State (5-1) was led by Ayoka Lee, who had 16 points. Serena Sundell scored 15 and Kennedy Taylor came off the bench to add 11 for the Wildcats. Kansas State: With her 16-point performance, Lee needs 48 points to pass Kendra Wecker (2001-05) for the Kansas State career scoring record. Wecker scored 2,333 points. Lee, the 2024-25 Preseason Big 12 Player of the Year, is averaging 15.3 points. Duke: Jackson hit her season average of 13.3 points by the 3:54 mark of the second quarter when her pull-up jumper gave her 14. The junior guard was 8 of 11 from the floor, including 4 of 5 from 3-point range, and had 20 points by halftime. With the Blue Devils trailing by six midway through the second quarter, Jackson triggered a 15-0 run with 13 of the team’s points to help Duke take a lead they’d never relinquish. Duke will face the winner of No. 9 Oklahoma-DePaul on Wednesday in the championship game, while Kansas State will face the loser in the consolation game. Get poll alerts and updates on AP Top 25 basketball throughout the season. Sign up here. AP women’s college basketball: and
Salesforce Grants Equity Awards to Tenyx, PredictSpring, and Zoomin Employees Under Its Inducement Equity Incentive PlanCalamos Convertible and High Income Fund ( NASDAQ:CHY – Get Free Report ) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 124,900 shares, a growth of 56.9% from the November 30th total of 79,600 shares. Based on an average daily trading volume, of 147,200 shares, the days-to-cover ratio is currently 0.8 days. Calamos Convertible and High Income Fund Trading Down 1.1 % Shares of Calamos Convertible and High Income Fund stock opened at $12.17 on Friday. Calamos Convertible and High Income Fund has a 52 week low of $10.77 and a 52 week high of $12.59. The company’s 50-day moving average price is $12.17 and its two-hundred day moving average price is $11.76. Calamos Convertible and High Income Fund Dividend Announcement The firm also recently announced a monthly dividend, which will be paid on Friday, January 10th. Investors of record on Monday, December 30th will be paid a dividend of $0.10 per share. This represents a $1.20 annualized dividend and a yield of 9.86%. The ex-dividend date is Monday, December 30th. Institutional Trading of Calamos Convertible and High Income Fund Calamos Convertible and High Income Fund Company Profile ( Get Free Report ) Calamos Convertible and High Income Fund is a closed ended fixed income mutual fund launched by Calamos Investments LLC. It is managed by Calamos Advisors LLC. The fund invests in the fixed income markets of the United States. It primarily invests in a diversified portfolio of convertible securities and high yield corporate bonds rated Ba or lower by Moody's or BB or lower by Standard & Poor's. Featured Stories Receive News & Ratings for Calamos Convertible and High Income Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calamos Convertible and High Income Fund and related companies with MarketBeat.com's FREE daily email newsletter .
DETROIT (AP) — Detroit Lions wide receiver Jameson Williams will not be charged with a crime after he was found with a gun in a car driven by his brother, a prosecutor said Monday. The gun on the floor was registered to Williams, but he didn't have a concealed-carry permit. His brother did. Prosecutor Kym Worthy said Michigan law is “far from clear” when applied to the 1 a.m. traffic stop on Oct. 8. “We really could not recall any case that had facts that mirrored this case,” she said. Williams was riding in a car driven by his brother when Detroit police stopped the vehicle for speeding. Williams said one of two guns in the car belonged to him and was registered. But without a concealed-pistol license, known as a CPL, a Michigan gun owner typically must place the weapon in a closed case while in a vehicle. A violation is a felony. In this case, Williams' brother had a permit. “The CPL holder here was the driver and had care, custody and control of the car," Worthy said. “Guidance is needed for the future on how many weapons can a valid CPL say that they have control over.” Williams obtained a CPL on Nov. 6, a month later, attorney Todd Flood said. “My client is thankful and humbled by the hard work Kym Worthy and her team put into this matter,” Flood said. During the traffic stop, Williams was handcuffed and placed in a patrol car before officers released him with his gun instead of taking him to a detention center. Williams, a first-round draft pick in 2022, has 29 catches for 602 yards and four touchdowns this season. AP NFL: https://apnews.com/hub/NFLCautious Fed, Mag 7 gains, US equities: Market Takeaways
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- CreateAI Holdings Inc., formerly TuSimple Holdings Inc. (OTCMKTS: TSPH) ("CreateAI" or the "Company"), a global artificial intelligence technology company, today announced shareholder voting results for its annual meeting of stockholders held on December 20, 2024 (the "Annual Meeting"). As of October 28, 2024 , the record date for the Annual Meeting, there were a total of 232,618,399 shares of common stock outstanding and entitled to vote at the Annual Meeting, comprised of 208,618,399 shares of Class A Common Stock (each with one vote per share) and 24,000,000 shares of Class B Common Stock (each with ten votes per share). At the Annual Meeting, holders of 207,347,538 shares of common stock, representing 423,347,538 votes, entitled to vote at the meeting were represented in person or by proxy and, therefore, a quorum constituted of the majority of the voting power of the shares of common stock issued and outstanding and entitled to vote at the Annual Meeting was present. The following is a brief description of each matter voted upon at the 2024 Annual Meeting and the numbers of votes cast for, withheld, or against, the number of abstentions, and the number of broker non-votes with respect to each other, as applicable. 1. Election of six nominees to serve on the Board of Directors (the "Board") for a term which will expire at the 2025 annual meeting of stockholders, or, if Proposal Two is adopted, to hold office until the annual meeting of stockholders in accordance with the class of director to which each nominee will be assigned. The following six directors were elected by the votes as indicated below. For Withheld Broker Non-Votes Cheng Lu 208,949,915 164,765,019 1 49,632,604 Mo Chen 208,946,146 164,768,788 1 49,632,604 James Lu 209,109,928 164,605,006 1 49,632,604 Zhen Tao 209,158,316 164,556,618 1 49,632,604 Albert Schultz 348,895,019 1 24,819,915 49,632,604 Jianan Hao 209,021,652 164,693,282 1 49,632,604 The totals above include the 240,000,000 votes represented by the Class B shares of Common Stock. 12,000,000 shares of Class B Common Stock (representing 120,000,00 votes) were voted "FOR" and 12,000,000 shares of Class B Common stock (representing 120,000,00 votes) were voted "WITHHELD" for each of the Directors other than Albert Schultz . All shares of Class B Common Stock were voted "FOR" the election of Albert Schultz . Excluding the 240,000,000 votes from the 24,000,000 shares of Class B Common Stock from the totals above, the 183,347,538 shares of Class A Common Stock were voted as indicated below. For Withheld Broker Non-Votes Cheng Lu 88,949,915 44,765,019 49,632,604 Mo Chen 88,946,146 44,768,788 49,632,604 James Lu 89,109,928 44,605,006 49,632,604 Zhen Tao 89,158,316 44,556,618 49,632,604 Albert Schultz 108,895,019 24,819,915 49,632,604 Jianan Hao 89,021,652 44,693,282 49,632,604 2. Amendment to the Company's Restated Certificate of Incorporation to classify the Board of Directors into three classes, with directors in each class to serve staggered three-year terms. Pursuant to the Restated Certificate of Incorporation, Proposal Two must receive the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, since directors representing two-thirds (2/3) of the total number of authorized directors have already approved. The amendment was not approved 2 by the votes as indicated below: For Against 1 Abstain Broker Non-Votes 208,955,668 164,659,652 99,614 49,632,604 Because Proposal Two was not approved, the six directors elected pursuant to Proposal One will serve on the Board for a term which will expire at the 2025 annual meeting of stockholders. 3. Ratification of the appointment of UHY LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 . The selection was ratified by the votes as indicated below: For Against 1 Abstain Broker Non-Votes 255,504,371 155,923,768 11,919,399 - Note 1: Includes 120,000,000 votes of the 12,000,000 shares of Class B Common Stock held by White Marble LLC and White Marble International Limited (together, the "White Marble Entities") controlled by Dr. Xiaodi Hou . Note 2: The White Marble Entities have filed an action in the Delaware Court of Chancery seeking a declaratory judgment that the voting agreement between White Marble and Mo Chen is invalid and White Marble, not Mo Chen , controls the vote. White Marble LLC v. Chen , C.A. No. 2024-1208-PAF (Del. Ch.) On December 13, 2024 , the Court entered an order that allows the Company to hold the vote on Proposal Two, and ordered that if Proposal Two is not approved at the Annual Meeting but the Court determines in the Action that Mo Chen , not the White Marble Entities, control how the White Marble Entities' Shares are voted, then the White Marble Entities' shares shall be deemed to have been voted in favor of Proposal Two at the Annual Meeting and that such vote shall stand. The vote totals above include the votes of the shares held by the White Marble Entities as voted by the White Marble Entities. If the shares held by the White Marble entities reflected in the totals above are deemed to have been voted in favor of Proposal Two, the Proposal will have passed. Accordingly, if the Court rules in Mo Chen's favor, Proposal Two will be deemed to have passed and the Company would be permitted to amend its Certificate of Incorporation to implement Proposal Two and each of the directors elected pursuant to Proposal One will serve on the Board until the annual meeting of stockholders in accordance with the class of director to which each nominee is assigned. About CreateAI CreateAI (formerly TuSimple) is a global artificial intelligence company with offices in US, China , and Japan . The company is pioneering the future of digital entertainment content production, seamlessly blending cutting-edge generative AI technology with the creativity of world-class talent. Our mission is to redefine the boundaries of what's possible in digital storytelling by developing immersive, captivating, and visually stunning experiences that resonate with audiences on a global scale. Investor Relations Contact: ICR for CreateAI CreateAI.IR@icrinc.com View original content to download multimedia: https://www.prnewswire.com/news-releases/createai-announces-results-of-2024-annual-meeting-of-stockholders-302338618.html SOURCE CreateAI Holdings IncComelec: Don't mix Traslacion, politics
Reform UK leader Nigel Farage has threatened to sue his Tory counterpart Kemi Badenoch if she fails to apologise for accusing the populist party of faking numbers that show Reform surpassed the Conservatives in paid members. The war of words broke out after Reform UK claimed on Boxing Day that it now has more members than the Tories. Using a live online ticker, the upstart party tracked the moment it had surpassed the latest declared membership numbers from the centuries-old Conservative Party. After Reform passed the threshold of 131,680 members (the latest account of membership released by the Tories in November), recently-installed Conservative leader Kemi Badenoch accused the party of using an automated online ticker rather than reflecting actual sign-ups. “Manipulating your own supporters at Xmas eh, Nigel?. It’s not real. It’s a fake... [the website has been] coded to tick up automatically,” she wrote on X. Badenoch also claimed that the Tories had “gained thousands of new members” after she was selected as leader in November. However, the party has yet to release such figures to the public. Following the accusation of faking its membership tally, Reform opened its books on the independent Nation Builder platform, which tracks political party membership, to several British media outlets, including Sky News. The broadcaster reported that it “was able to verify that the number of memberships in Reform’s NationBuilder account matched the number presented on their on-site ticker.” Mr Farage has branded Badenoch “disgraceful” for the accusations and demanded that she apologise for the “intemperate outburst.” When asked if he planned on suing the Conservative leader for libel, the Reform leader said: “I’m going to take some action in the next couple of days. I’ve got to decide exactly what it is, but I’m certainly not going to take it lying down.” “I think it’s an absolutely outrageous thing for her to have said... know she’s got a very bad temper. I know she’s well known for lashing out at people, but I am not at all happy, and I’m going to take some action.” After Reform surpassed the latest Tory figures, Mr Farage hailed the achievement as a “ historic moment ,” saying: “The youngest political party in British politics has just overtaken the oldest political party in the world.” “Reform UK are now the real opposition,” he declared. While the so-called Conservatives continue to reel from their devastating election defeat in July and the fledgling left-wing Labour government continues to haemorrhage support, Reform has steadily risen in the ranks. Despite only returning to frontline politics in June, Farage is now the odds-on favourite to become the next UK prime minister, according to betting agency Ladbrokes, demonstrating the degree to which the political sands are shifting in Britain.Is Outlook down? Thousands of Microsoft 365 users report outage issues.